Page last updated: 2024-08-23

pravastatin and serine

pravastatin has been researched along with serine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Crisby, M; Högberg, J; Pääjärvi, G; Roudier, E; Stenius, U	1
Gao, L; Ge, JB; Xu, B; Yao, K	1

Other Studies

2 other study(ies) available for pravastatin and serine

Article	Year
HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:3 Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Enzyme Inhibitors; Female; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Insulin; Liver; Liver Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pravastatin; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53	2005
Pravastatin activates platelet nitric oxide synthase (NOS) in patients with type 2 diabetes mellitus and NOS activation is accompanied by serine phosphorylation. Chinese medical journal, 2005, Oct-05, Volume: 118, Issue:19 Topics: Blood Platelets; Diabetes Mellitus, Type 2; Enzyme Activation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Serine	2005

Article

Year

HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:3

Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Enzyme Inhibitors; Female; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Insulin; Liver; Liver Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pravastatin; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53

2005

Pravastatin activates platelet nitric oxide synthase (NOS) in patients with type 2 diabetes mellitus and NOS activation is accompanied by serine phosphorylation.

Chinese medical journal, 2005, Oct-05, Volume: 118, Issue:19

Topics: Blood Platelets; Diabetes Mellitus, Type 2; Enzyme Activation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Serine

2005